CBD FOR PAIN : WHAT DOES THE SCIENCE SAY ? A new book by three distinguished scientists reviews the current status of CBD as a treatment for acute and chronic illness. By Linda A. Parker, Erin M. Rock, and Raphael Mechoulam on October 04, 2022 Excerpted from CBD: What Does the Science Say ? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by MIT Press (2022, 309 pp.). A large proportion of medicinal cannabis patients are using cannabis to treat pain syndromes, particularly for chronic pain alleviation. Cannabis use for unmanageable pain has been shown to reduce the dose of opiates [...]
Lire la suiteLe Petit Livre du Cannabis Médical Nicolas Authier, Editions First, 2021, 149 pages Sommaire Petit livre Cannabis Médical - N Authier
Lire la suiteCannabis Misconceptions Still Common Among MS Clinicians Nancy Melville June 05, 2020 https://www.medscape.com/viewarticle/931872?nlid=135873_425&src=WNL_mdplsfeat_200609_mscpedit_psyc&uac=292598PZ&spon=12&impID=2413707&faf=1 Despite the ever-increasing acceptance of medical cannabis and its notably common use in patients with multiple sclerosis (MS), clinicians treating those patients still may be poorly informed about risks, benefits, regulations, and proper uses, experts say. "There is evidence of a 'clinical void,' with clinicians on one side and people with MS and other conditions on the other that doesn't usually exist regarding therapies that people with MS are using," said Allen C. Bowling, MD, PhD, director of the NeuroHealth Institute and clinical professor of neurology at the University of Colorado, in Aurora. His [...]
Lire la suiteRelated Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study Francesco Patti, Clara Grazia Chisari, Claudio Solaro, Maria Donata Benedetti , Eliana Berra , Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla , Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia, SA.FE. group Doi : 10.1007/s10072-020-04413-6 Abstract Introduction : The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed [...]
Lire la suiteThe Broad Concept of “Spasticity- Plus Syndrome” in Multiple Sclerosis : A Possible New Concept in the Management of Multiple Sclerosis Symptoms Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto and Lluis Ramió Frontiers in Neurology , 2020 | Volume 11 | Article 152 doi : 10.3389/fneur.2020.00152 Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic [...]
Lire la suite